WW Sequence Acquisition Narrows Noom Gap

WW bought Sequence to replace a shrinking meeting based diet business with a higher frequency medical subscription business. Sequence gave WW a ready made telehealth engine with about 24,000 members and roughly $25M in annual revenue run rate by February 2023, then WW folded it into WeightWatchers Clinic to sell medication access plus food guidance and habit coaching in one app. That puts WW much closer to Noom, which had already launched Noom Med in May 2023 to combine GLP-1 prescribing with its psychology based program.1 2 3 4 5

• The deal was structured around speed, not just cost. WW announced $100M at close, made up of cash and stock, with total merger consideration later disclosed at $132M before adjustments. That matters because buying Sequence was faster than building a national clinician network, pharmacy workflows, and obesity care protocols from scratch.2 3
• WW needed a new growth lane. Its 2023 revenue fell to $889.6M from $1.21B in 2021, showing how far the legacy subscription model had slipped. Sequence let WW move from weekly weigh in style support into ongoing obesity treatment, where the consumer pays for clinician access and often for medication too.4
• The competitive gap with Noom narrowed, but did not disappear. Noom was already mobile native and behavior first, and by 2023 had launched Noom Med inside its existing app. WW had to integrate a separate telehealth asset into a legacy brand, while Noom extended an already digital product into prescribing.1 5 6

This pushes the weight loss market toward bundled obesity care, where the winner is the app that can acquire users cheaply, get them a prescription fast, and keep them engaged after the first months on GLP-1s. WW turned itself into a closer Noom analogue with the Sequence deal, but the next phase depends on who best combines medication, coaching, and retention in one digital workflow.1 3 5 6